Where along the contiuum of vaccine willingness does the the majority of America sit as the country enters the 2023-2024 respiratory virus season?
Patient Care recently spoke with infectious disease specialist William Schaffner, MD, of Vanderbilt University and family physician Chuck Vega, MD, of the University of California Irvine to find out how the 2 health care leaders would answer the question. That conversation follows in the video below.
William Schaffner, MD, is professor of infectious disease and preventive medicine in the Department of Health Policy, and professor of medicine in the Division of Infectious Diseases at Vanderbilt University School of Medicine in Nashville, TN. Twitter: @NFIDvaccines
Charles Vega, MD is health sciences clinical professor and associate dean for Diversity and Inclusion at the UC Irvine School of Medicine where he also serves as executive director for the UC Irvine Program in Medical Education for the Latino Community.
For other conversations in our series with Drs William Schaffner and Chuck Vega:
Keep the Vaccination Conversation Going—and Cheerlead, Too
3 Dangerous Respiratory Viruses, 3 Robust Vaccines, 3 Shots at Broad Protection This Year
The Respiratory Syncytial Virus Vaccine for Older Adults: The New Shot on the Block
Respiratory Virus Season 2023-2024 is Shaping Up to be a Transitional One: Expert Interview